CXB 909

Drug Profile

CXB 909

Alternative Names: CXB909; KP 544; KRX-0501

Latest Information Update: 27 Jun 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Krenitsky Pharmaceuticals
  • Developer Keryx Biopharmaceuticals
  • Class Antidementias; Nootropics; Pyrimidines; Small molecules
  • Mechanism of Action Choline kinase stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Neurological disorders

Most Recent Events

  • 27 Jun 2013 Discontinued - Phase-I for Neurological disorders in USA (PO)
  • 27 Jun 2013 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 09 Dec 2011 US FDA approves IND application for CXB 909 in Alzheimer′s disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top